KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Cash & Current Investments (2018 - 2025)

Historic Cash & Current Investments for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $212.8 million.

  • Adaptive Biotechnologies' Cash & Current Investments fell 1255.91% to $212.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $212.8 million, marking a year-over-year decrease of 1255.91%. This contributed to the annual value of $222.3 million for FY2024, which is 3582.76% down from last year.
  • Adaptive Biotechnologies' Cash & Current Investments amounted to $212.8 million in Q3 2025, which was down 1255.91% from $197.9 million recorded in Q2 2025.
  • Adaptive Biotechnologies' 5-year Cash & Current Investments high stood at $714.3 million for Q1 2021, and its period low was $193.4 million during Q1 2025.
  • Its 5-year average for Cash & Current Investments is $372.6 million, with a median of $363.6 million in 2022.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first plummeted by 5029.94% in 2021, then skyrocketed by 4110.76% in 2022.
  • Quarter analysis of 5 years shows Adaptive Biotechnologies' Cash & Current Investments stood at $353.1 million in 2021, then soared by 41.11% to $498.2 million in 2022, then crashed by 30.47% to $346.4 million in 2023, then crashed by 35.83% to $222.3 million in 2024, then dropped by 4.28% to $212.8 million in 2025.
  • Its last three reported values are $212.8 million in Q3 2025, $197.9 million for Q2 2025, and $193.4 million during Q1 2025.